Salt Lake City, Utah, USA, May 18, 2016 – Fresh Medical Laboratories, Inc., doing business as ProLungdx™, today announced the initial results of its ongoing European Lung Cancer Registry. When the Electro Pulmonary Nodule (EPN) Scan was administered to patients with lung nodules suspicious for cancer, the scan demonstrated results consistent with earlier research performed at Johns Hopkins and published in the Journal of Thoracic Oncology. The non-invasive test correctly identified 23 out of 27, or 85% of patients where malignancy was confirmed by tissue biopsy. More results are expected soon, as the EPN Scan has been administered to more than 170 patients in Europe and over 100 of these are enrolled in the registry. Other research is underway at eight cancer centers in the US and four in Asia.
“The key to improved survival is understanding the risk associated with a suspicious pulmonary nodule. It’s heartening to see such positive results coming from leading European interventional pulmonologists. They are pioneers focused on immediate evaluation of indeterminate lung nodules. Compared with the standard of care, we believe that the EPN Scan can increase the time available for treatment and may ultimately save lives,” said Steven Eror, President and CEO of ProLungdx.
The EPN Scan uses its novel mass averaging bioconductance technology to evaluate patients who discover lung nodules incidentally or by lung cancer screening. As the low-dose computed tomography (LDCT) screen becomes widespread, risk stratification tools, such as ProLungdx’s EPN Scan, will be essential to aiding physicians to evaluate the risk of cancer while treatment options are still available.
ProLungdx is a privately held, US-based medical technology company that develops, manufactures and sells non-invasive medical technology to aid in the early detection and diagnosis of lung […]